Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

H.C. Wainwright reaffirmed its Buy rating on Rezolute (NASDAQ:RZLT) with a price target of $14.00. The company, currently trading at $5.50 with a market capitalization of $319 million, has delivered ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The state of California banned the Red No. 3 dye and three other food additives in 2023, which gave manufacturers until 2027 ...

Pro-choice lawmakers, doctors and advocates have argued the science is settled when it comes to the controversial abortion pill mifepristone. They say the drug is safe and that it needs to be widely ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Pro-choice advocates say the science is settled on the abortion pill mifepristone, but critics argue that better safeguards ...